The FDA on December 6, 2018 approved TECENTRIQ® in combination with AVASTIN® (Bevacizumab), TAXOL® (Paclitaxel), and Carboplatin for the first-line treatment of patients with metastatic non-squamous, Non-Small Cell Lung Cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations. TECENTRIQ® is a product of Genentech, Inc.
Bottom Ad
Advertisement
Subscribe
